<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893971</url>
  </required_header>
  <id_info>
    <org_study_id>PT0030901</org_study_id>
    <nct_id>NCT00893971</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Single Dose, Four-period, Four-treatment, Cross-over Study Evaluating the Safety of PT001, PT003, PT005 Administered Individually and PT001 + PT005 Delivered Together in Separate Inhalers in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of a single dose of PT003 compared with
      single doses of PT001 and PT005, and compared with PT001 plus PT005 delivered together as two
      separate single doses in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms of Dry Mouth</measure>
    <time_frame>12 hours</time_frame>
    <description>Number of participants reporting dry mouth at 12 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms of Tremor</measure>
    <time_frame>12 hours</time_frame>
    <description>Number of participants reporting tremor at 12 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Chemistry Change From Baseline</measure>
    <time_frame>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</time_frame>
    <description>Series of 11 blood chemistries assessed throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology Change From Baseline</measure>
    <time_frame>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</time_frame>
    <description>Hematology assessments taken throughout the study Hematocrit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology Change From Baseline</measure>
    <time_frame>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</time_frame>
    <description>Hematology assessments taken throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology Change From Baseline</measure>
    <time_frame>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</time_frame>
    <description>Hematology assessments taken throughout the study Hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate Change From Baseline</measure>
    <time_frame>12 hours</time_frame>
    <description>Change from baseline for heart rate 12-hours post-dose Heart rate (bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Sign Change Baseline; Blood Pressure</measure>
    <time_frame>12 hours</time_frame>
    <description>Vital sign change baseline; blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Sign Change From Baseline, SpO2</measure>
    <time_frame>12 hours</time_frame>
    <description>Vital Sign Change from baseline 12-hours post-dose SpO2 (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Change From Baseline</measure>
    <time_frame>12 hours</time_frame>
    <description>Change from baseline for ECG parameters 12-hours post-dose Ventricular rate (bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Change From Baseline</measure>
    <time_frame>12 hours</time_frame>
    <description>Change from baseline for ECG parameters 12-hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry Change From Baseline</measure>
    <time_frame>12 hours</time_frame>
    <description>Change from baseline for spirometery measures 12-hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry Change From Baseline</measure>
    <time_frame>12 hours</time_frame>
    <description>Change from baseline for spirometery measures 12-hours post-dose (FEV1 % predicted)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry Change From Baseline</measure>
    <time_frame>12 hours</time_frame>
    <description>Change from baseline for spirometery measures 12-hours post-dose FEV/FVC (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry Change From Baseline</measure>
    <time_frame>12 hours</time_frame>
    <description>Change from baseline for spirometery measures 12-hours post-dose PEFR (L/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Potassium Change From Baseline</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Glycopyrrolate PK Parameters</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glycopyrrolate PK Parameters AUC0-inf (h*pg/mL)</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glycopyrrolate PK Parameters (Tmax)</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glycopyrrolate PK Parameters (t1/2)</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glycopyrrolate PK Parameters Cmax (pg/mL)</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glycopyrrolate PK Parameters (ke)</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Formoterol PK Parameters</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Various pharmacokinetic parameters for plasma formoterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Formoterol PK Parameters AUC0-inf (h*pg/mL)</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Various pharmacokinetic parameters for plasma formoterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Formoterol PK Parameters (Tmax)</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Various pharmacokinetic parameters for plasma formoterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Formoterol PK Parameters (t1/2)</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Various pharmacokinetic parameters for plasma formoterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Formoterol PK Parameters (Cmax)</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Pharmacokinetic parameters for plasma formoterol Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Formoterol PK Parameters (ke)</measure>
    <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
    <description>Pharmacokinetic parameters for plasma formoterol ke</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT001 18 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT005 2.4 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT003 (PT001 18 μg / 2.4 μg PT005)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 18 μg + PT005 2.4 μg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001</intervention_name>
    <description>Inhaled PT001, single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT005</intervention_name>
    <description>Inhaled PT005, single dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT003</intervention_name>
    <description>Inhaled PT003, single dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 + PT005</intervention_name>
    <description>Inhaled PT001 + PT005, single dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide signed written informed consent

          -  18-55 years of age

          -  Healthy subjects confirmed by medical history, physical examination, vital signs,
             pulmonary function tests, electrocardiogram and clinical laboratory tests

          -  Female subjects of child-bearing potential who are sexually active must be willing to
             undergo a pregnancy test and agree to use two forms of contraception

          -  Body mass index (BMI) between 18.5 and 30, inclusive

          -  Non-smokers for at least 6 months prior to screening

          -  Pulmonary function tests within normal limits

          -  Willing to remain at the study center for at least 12-24 hours on each test day

          -  Venous access in both arms to allow collection of numerous blood samples

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Clinically significant medical conditions

          -  Viral illness within the last 30 days

          -  Symptomatic prostatic hypertrophy or bladder neck obstruction

          -  Known narrow-angle glaucoma

          -  History of bowel obstruction

          -  Clinically significant abnormal electrocardiogram

          -  Positive Hepatitis B surface antigen or positive Hepatitis C antibody

          -  Positive screening test for HIV antibodies

          -  History of hypersensitivity to any beta2-agonists, anticholinergics, or any component
             of the MDI

          -  Known or suspected history of alcohol or drug abuse within the last 2-years

          -  Greater than normal alcohol consumption

          -  Ingestion of any poppy seeds within the 48 hours prior to the screening

          -  Ingestion of any poppy seeds within the 48 hours prior to, or any alcohol, xanthines
             or grapefruit-containing foods or beverages within the 24 hours prior to, or during,
             each confinement

          -  Positive breath alcohol result

          -  Positive urine drug screen

          -  Use of any beta2-agonists,or anticholinergics prior to the recruitment interview

          -  Lower respiratory tract infections requiring antibiotics in the previous 6 weeks

          -  Use of any other prescription medication

          -  Use of any over the counter product, herbal product, diet aid, hormone supplement

          -  Donation &gt; 450 ml of blood within 8 weeks of first treatment dose

          -  Clinically significant vital sign abnormality

          -  Clinically significant biochemical, hematological or urinalysis abnormality

          -  Affiliations with investigator site

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives prior to screening, whichever is
             longer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Joanne Marjason</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <results_first_submitted>May 24, 2016</results_first_submitted>
  <results_first_submitted_qc>March 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2017</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at a single site in Australia from May 2009 through July 2009. Study participation was a maximum of 7 weeks.</recruitment_details>
      <pre_assignment_details>Study evaluating a single administration of inhaled treatment (PT001, PT003, PT005 and PT001+PT005 delivered from separate inhalers as a loose combination).Each subject was randomized to 1 of 4 sequences. Each sequence included the four treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All patients randomized</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo + GP MDI (PT001)</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo + GFF MDI (PT003)</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo + FF MDI (PT005)</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI (PT001) + FF MDI (PT005)</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Any treatment arm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Symptoms of Dry Mouth</title>
        <description>Number of participants reporting dry mouth at 12 hours post-dose</description>
        <time_frame>12 hours</time_frame>
        <population>All subjects in the Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Dry Mouth</title>
          <description>Number of participants reporting dry mouth at 12 hours post-dose</description>
          <population>All subjects in the Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immediately pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">If no dry mouth is present up to the 2 hr time point, then no further assessments are required. If dry mouth is present, then assessments are continued until the AE is resolved.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">If no dry mouth is present up to the 2 hr time point, then no further assessments are required. If dry mouth is present, then assessments are continued until the AE is resolved.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">If no dry mouth is present up to the 2 hr time point, then no further assessments are required. If dry mouth is present, then assessments are continued until the AE is resolved.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Symptoms of Tremor</title>
        <description>Number of participants reporting tremor at 12 hours post-dose</description>
        <time_frame>12 hours</time_frame>
        <population>All subjects in the Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Tremor</title>
          <description>Number of participants reporting tremor at 12 hours post-dose</description>
          <population>All subjects in the Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immediately pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                    <measurement group_id="O2" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                    <measurement group_id="O3" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                    <measurement group_id="O4" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                    <measurement group_id="O2" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                    <measurement group_id="O3" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                    <measurement group_id="O4" value="NA">If no tremor was present at the previous 2-hour time point, no further assessment was required</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Chemistry Change From Baseline</title>
        <description>Series of 11 blood chemistries assessed throughout the study</description>
        <time_frame>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</time_frame>
        <population>All patients in the Safety Population that had a valid measurement for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Chemistry Change From Baseline</title>
          <description>Series of 11 blood chemistries assessed throughout the study</description>
          <population>All patients in the Safety Population that had a valid measurement for the parameter</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="-3" upper_limit="4"/>
                    <measurement group_id="O2" value="0.78" lower_limit="-1" upper_limit="3"/>
                    <measurement group_id="O3" value="0.35" lower_limit="-2" upper_limit="6"/>
                    <measurement group_id="O4" value="0.6" lower_limit="-2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" lower_limit="-7" upper_limit="2"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-4" upper_limit="4"/>
                    <measurement group_id="O3" value="-0.75" lower_limit="-5" upper_limit="6"/>
                    <measurement group_id="O4" value="-1.2" lower_limit="-3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="-0.9" upper_limit="1.4"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-1.3" upper_limit="1.8"/>
                    <measurement group_id="O3" value="-0.11" lower_limit="-2.6" upper_limit="1.5"/>
                    <measurement group_id="O4" value="-0.33" lower_limit="-3.3" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.1" upper_limit="0.08"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.2" upper_limit="0.06"/>
                    <measurement group_id="O3" value="-0.03" lower_limit="-0.21" upper_limit="0.08"/>
                    <measurement group_id="O4" value="-0.01" lower_limit="-0.11" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="-2" upper_limit="4"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-4" upper_limit="2"/>
                    <measurement group_id="O3" value="0.44" lower_limit="-5" upper_limit="6"/>
                    <measurement group_id="O4" value="0.47" lower_limit="-5" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-2.5" upper_limit="1.1"/>
                    <measurement group_id="O2" value="-0.34" lower_limit="-2.4" upper_limit="1.2"/>
                    <measurement group_id="O3" value="-0.34" lower_limit="-2" upper_limit="1.1"/>
                    <measurement group_id="O4" value="0.45" lower_limit="-1.9" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Chemistry Change From Baseline</title>
        <description>Series of 11 blood chemistries assessed throughout the study</description>
        <time_frame>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</time_frame>
        <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Chemistry Change From Baseline</title>
          <description>Series of 11 blood chemistries assessed throughout the study</description>
          <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="-11" upper_limit="11"/>
                    <measurement group_id="O2" value="1.45" lower_limit="-15" upper_limit="12"/>
                    <measurement group_id="O3" value="0.44" lower_limit="-14" upper_limit="11"/>
                    <measurement group_id="O4" value="-0.8" lower_limit="-13" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-6" upper_limit="3"/>
                    <measurement group_id="O2" value="-2.18" lower_limit="-5" upper_limit="0"/>
                    <measurement group_id="O3" value="-2.32" lower_limit="-6" upper_limit="1"/>
                    <measurement group_id="O4" value="-2.07" lower_limit="-10" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Chemistry Change From Baseline</title>
        <description>Series of 11 blood chemistries assessed throughout the study</description>
        <time_frame>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</time_frame>
        <population>All patients in the Safety Population that had a valid measurement for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Chemistry Change From Baseline</title>
          <description>Series of 11 blood chemistries assessed throughout the study</description>
          <population>All patients in the Safety Population that had a valid measurement for the parameter</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="-3" upper_limit="10"/>
                    <measurement group_id="O2" value="3.59" lower_limit="-3" upper_limit="12"/>
                    <measurement group_id="O3" value="1.39" lower_limit="-9" upper_limit="9"/>
                    <measurement group_id="O4" value="2" lower_limit="-9" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-6" upper_limit="5"/>
                    <measurement group_id="O2" value="-1.21" lower_limit="-8" upper_limit="4"/>
                    <measurement group_id="O3" value="-0.41" lower_limit="-5" upper_limit="5"/>
                    <measurement group_id="O4" value="-0.33" lower_limit="-5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" lower_limit="-10" upper_limit="7"/>
                    <measurement group_id="O2" value="0.25" lower_limit="-5" upper_limit="6"/>
                    <measurement group_id="O3" value="-2.91" lower_limit="-14" upper_limit="4"/>
                    <measurement group_id="O4" value="-1.67" lower_limit="-10" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology Change From Baseline</title>
        <description>Hematology assessments taken throughout the study Hematocrit</description>
        <time_frame>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</time_frame>
        <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology Change From Baseline</title>
          <description>Hematology assessments taken throughout the study Hematocrit</description>
          <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
          <units>% of Red Blood Cells in the blood</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.07" upper_limit="0.03"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.02" upper_limit="0.04"/>
                    <measurement group_id="O3" value="0.01" lower_limit="-0.02" upper_limit="0.03"/>
                    <measurement group_id="O4" value="0.01" lower_limit="-0.02" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology Change From Baseline</title>
        <description>Hematology assessments taken throughout the study</description>
        <time_frame>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</time_frame>
        <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology Change From Baseline</title>
          <description>Hematology assessments taken throughout the study</description>
          <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
          <units>(10^9 cells/L)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WCC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.93" lower_limit="-13" upper_limit="39"/>
                    <measurement group_id="O2" value="20.61" lower_limit="-1" upper_limit="55"/>
                    <measurement group_id="O3" value="10.8" lower_limit="-31" upper_limit="43"/>
                    <measurement group_id="O4" value="20.33" lower_limit="-17" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="-1" upper_limit="3"/>
                    <measurement group_id="O2" value="0.88" lower_limit="-1" upper_limit="3"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="0.67" lower_limit="-4" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology Change From Baseline</title>
        <description>Hematology assessments taken throughout the study Hemoglobin</description>
        <time_frame>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</time_frame>
        <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology Change From Baseline</title>
          <description>Hematology assessments taken throughout the study Hemoglobin</description>
          <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" lower_limit="-24" upper_limit="11"/>
                    <measurement group_id="O2" value="2.95" lower_limit="-6" upper_limit="10"/>
                    <measurement group_id="O3" value="1.73" lower_limit="-4" upper_limit="10"/>
                    <measurement group_id="O4" value="3.33" lower_limit="-9" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate Change From Baseline</title>
        <description>Change from baseline for heart rate 12-hours post-dose Heart rate (bpm)</description>
        <time_frame>12 hours</time_frame>
        <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Change From Baseline</title>
          <description>Change from baseline for heart rate 12-hours post-dose Heart rate (bpm)</description>
          <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-7" upper_limit="13"/>
                    <measurement group_id="O2" value="4.4" lower_limit="-12" upper_limit="21"/>
                    <measurement group_id="O3" value="2.9" lower_limit="-3" upper_limit="11"/>
                    <measurement group_id="O4" value="1.8" lower_limit="-13" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Sign Change Baseline; Blood Pressure</title>
        <description>Vital sign change baseline; blood pressure</description>
        <time_frame>12 hours</time_frame>
        <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Sign Change Baseline; Blood Pressure</title>
          <description>Vital sign change baseline; blood pressure</description>
          <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure (mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="-14" upper_limit="18"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-20" upper_limit="14"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-9" upper_limit="14"/>
                    <measurement group_id="O4" value="0.4" lower_limit="-8" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure (mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="-8" upper_limit="24"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-13" upper_limit="10"/>
                    <measurement group_id="O3" value="0.6" lower_limit="-12" upper_limit="12"/>
                    <measurement group_id="O4" value="1.6" lower_limit="-14" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Sign Change From Baseline, SpO2</title>
        <description>Vital Sign Change from baseline 12-hours post-dose SpO2 (%)</description>
        <time_frame>12 hours</time_frame>
        <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Sign Change From Baseline, SpO2</title>
          <description>Vital Sign Change from baseline 12-hours post-dose SpO2 (%)</description>
          <population>All subjects in the Safety Population that had a valid measurement for the parameter</population>
          <units>% blood oxygen saturation level</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-2" upper_limit="2"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-1" upper_limit="3"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O4" value="0.1" lower_limit="-1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Change From Baseline</title>
        <description>Change from baseline for ECG parameters 12-hours post-dose Ventricular rate (bpm)</description>
        <time_frame>12 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Change From Baseline</title>
          <description>Change from baseline for ECG parameters 12-hours post-dose Ventricular rate (bpm)</description>
          <population>Safety population</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-7" upper_limit="9"/>
                    <measurement group_id="O2" value="4.7" lower_limit="-18" upper_limit="22"/>
                    <measurement group_id="O3" value="5.2" lower_limit="-4" upper_limit="25"/>
                    <measurement group_id="O4" value="4.0" lower_limit="-9" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Change From Baseline</title>
        <description>Change from baseline for ECG parameters 12-hours post-dose</description>
        <time_frame>12 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Change From Baseline</title>
          <description>Change from baseline for ECG parameters 12-hours post-dose</description>
          <population>Safety population</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" lower_limit="-126" upper_limit="10"/>
                    <measurement group_id="O2" value="-8.3" lower_limit="-20" upper_limit="2"/>
                    <measurement group_id="O3" value="-5.3" lower_limit="-24" upper_limit="24"/>
                    <measurement group_id="O4" value="-10.4" lower_limit="-34" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-10" upper_limit="4"/>
                    <measurement group_id="O2" value="-5.4" lower_limit="-18" upper_limit="10"/>
                    <measurement group_id="O3" value="0.4" lower_limit="-10" upper_limit="42"/>
                    <measurement group_id="O4" value="-2.0" lower_limit="-12" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" lower_limit="-32" upper_limit="4"/>
                    <measurement group_id="O2" value="-9.4" lower_limit="-42" upper_limit="20"/>
                    <measurement group_id="O3" value="-10.1" lower_limit="-60" upper_limit="16"/>
                    <measurement group_id="O4" value="-12.8" lower_limit="-26" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" lower_limit="-24" upper_limit="18"/>
                    <measurement group_id="O2" value="5.3" lower_limit="-36" upper_limit="41"/>
                    <measurement group_id="O3" value="5.4" lower_limit="-17" upper_limit="39"/>
                    <measurement group_id="O4" value="-2.1" lower_limit="-26" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" lower_limit="-25" upper_limit="12"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-19" upper_limit="16"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-23" upper_limit="21"/>
                    <measurement group_id="O4" value="-5.9" lower_limit="-18" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spirometry Change From Baseline</title>
        <description>Change from baseline for spirometery measures 12-hours post-dose</description>
        <time_frame>12 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry Change From Baseline</title>
          <description>Change from baseline for spirometery measures 12-hours post-dose</description>
          <population>Safety population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1 (L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.260" lower_limit="-0.28" upper_limit="0.49"/>
                    <measurement group_id="O2" value="0.148" lower_limit="-0.53" upper_limit="0.43"/>
                    <measurement group_id="O3" value="0.202" lower_limit="-0.27" upper_limit="0.71"/>
                    <measurement group_id="O4" value="0.195" lower_limit="-0.33" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC (L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.145" lower_limit="-0.51" upper_limit="0.47"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.82" upper_limit="0.44"/>
                    <measurement group_id="O3" value="0.082" lower_limit="-0.49" upper_limit="0.53"/>
                    <measurement group_id="O4" value="0.045" lower_limit="-0.64" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spirometry Change From Baseline</title>
        <description>Change from baseline for spirometery measures 12-hours post-dose (FEV1 % predicted)</description>
        <time_frame>12 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry Change From Baseline</title>
          <description>Change from baseline for spirometery measures 12-hours post-dose (FEV1 % predicted)</description>
          <population>Safety population</population>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="-8" upper_limit="12"/>
                    <measurement group_id="O2" value="4.5" lower_limit="-12" upper_limit="12"/>
                    <measurement group_id="O3" value="5.2" lower_limit="-8" upper_limit="15"/>
                    <measurement group_id="O4" value="5.0" lower_limit="-7" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spirometry Change From Baseline</title>
        <description>Change from baseline for spirometery measures 12-hours post-dose FEV/FVC (%)</description>
        <time_frame>12 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry Change From Baseline</title>
          <description>Change from baseline for spirometery measures 12-hours post-dose FEV/FVC (%)</description>
          <population>Safety population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="-4" upper_limit="10"/>
                    <measurement group_id="O2" value="3.4" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O3" value="3.2" lower_limit="-4" upper_limit="9"/>
                    <measurement group_id="O4" value="3.6" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spirometry Change From Baseline</title>
        <description>Change from baseline for spirometery measures 12-hours post-dose PEFR (L/min)</description>
        <time_frame>12 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry Change From Baseline</title>
          <description>Change from baseline for spirometery measures 12-hours post-dose PEFR (L/min)</description>
          <population>Safety population</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" lower_limit="0" upper_limit="93"/>
                    <measurement group_id="O2" value="32.1" lower_limit="-120" upper_limit="150"/>
                    <measurement group_id="O3" value="40.1" lower_limit="-63" upper_limit="135"/>
                    <measurement group_id="O4" value="31.6" lower_limit="-99" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glycopyrrolate PK Parameters</title>
        <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glycopyrrolate PK Parameters</title>
          <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-tlast (h*pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.6" spread="76.7" lower_limit="-0.28" upper_limit="0.49"/>
                    <measurement group_id="O2" value="100.1" spread="43.1" lower_limit="-0.27" upper_limit="0.71"/>
                    <measurement group_id="O3" value="78.4" spread="36.2" lower_limit="-0.33" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-12 (h*pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.7" spread="76.5" lower_limit="-8" upper_limit="12"/>
                    <measurement group_id="O2" value="100.6" spread="42.4" lower_limit="-8" upper_limit="15"/>
                    <measurement group_id="O3" value="80.1" spread="34.9" lower_limit="-7" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glycopyrrolate PK Parameters AUC0-inf (h*pg/mL)</title>
        <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glycopyrrolate PK Parameters AUC0-inf (h*pg/mL)</title>
          <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.4" spread="88.6"/>
                    <measurement group_id="O2" value="137.2" spread="55.4"/>
                    <measurement group_id="O3" value="100.8" spread="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glycopyrrolate PK Parameters (Tmax)</title>
        <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glycopyrrolate PK Parameters (Tmax)</title>
          <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.14" lower_limit="-0.51" upper_limit="0.47"/>
                    <measurement group_id="O2" value="0.07" spread="0.06" lower_limit="-0.49" upper_limit="0.53"/>
                    <measurement group_id="O3" value="0.06" spread="0.03" lower_limit="-0.64" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glycopyrrolate PK Parameters (t1/2)</title>
        <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glycopyrrolate PK Parameters (t1/2)</title>
          <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.34" spread="1.78"/>
                    <measurement group_id="O2" value="5.12" spread="1.61"/>
                    <measurement group_id="O3" value="5.12" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glycopyrrolate PK Parameters Cmax (pg/mL)</title>
        <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glycopyrrolate PK Parameters Cmax (pg/mL)</title>
          <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" spread="40.9" lower_limit="-4" upper_limit="10"/>
                    <measurement group_id="O2" value="77.8" spread="72.0" lower_limit="-4" upper_limit="9"/>
                    <measurement group_id="O3" value="44.4" spread="18.3" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glycopyrrolate PK Parameters (ke)</title>
        <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glycopyrrolate PK Parameters (ke)</title>
          <description>Various pharmacokinetic parameters for plasma glycopyrrolate</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.143" spread="0.047"/>
                    <measurement group_id="O2" value="0.147" spread="0.042"/>
                    <measurement group_id="O3" value="0.155" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Formoterol PK Parameters</title>
        <description>Various pharmacokinetic parameters for plasma formoterol</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Formoterol PK Parameters</title>
          <description>Various pharmacokinetic parameters for plasma formoterol</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-tlast (h*pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="12.3" lower_limit="-120" upper_limit="150"/>
                    <measurement group_id="O2" value="61.2" spread="16.5" lower_limit="-63" upper_limit="135"/>
                    <measurement group_id="O3" value="57.9" spread="16.3" lower_limit="-99" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-12 (h*pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" spread="12.2"/>
                    <measurement group_id="O2" value="61.2" spread="16.6"/>
                    <measurement group_id="O3" value="57.8" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Formoterol PK Parameters AUC0-inf (h*pg/mL)</title>
        <description>Various pharmacokinetic parameters for plasma formoterol</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Formoterol PK Parameters AUC0-inf (h*pg/mL)</title>
          <description>Various pharmacokinetic parameters for plasma formoterol</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="8.3"/>
                    <measurement group_id="O2" value="76.4" spread="18.5"/>
                    <measurement group_id="O3" value="67.0" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Formoterol PK Parameters (Tmax)</title>
        <description>Various pharmacokinetic parameters for plasma formoterol</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Formoterol PK Parameters (Tmax)</title>
          <description>Various pharmacokinetic parameters for plasma formoterol</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.31" lower_limit="-120" upper_limit="150"/>
                    <measurement group_id="O2" value="0.27" spread="0.59" lower_limit="-63" upper_limit="135"/>
                    <measurement group_id="O3" value="0.43" spread="0.46" lower_limit="-99" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Formoterol PK Parameters (t1/2)</title>
        <description>Various pharmacokinetic parameters for plasma formoterol</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Formoterol PK Parameters (t1/2)</title>
          <description>Various pharmacokinetic parameters for plasma formoterol</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12" spread="1.10"/>
                    <measurement group_id="O2" value="5.28" spread="1.02"/>
                    <measurement group_id="O3" value="5.8" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Formoterol PK Parameters (Cmax)</title>
        <description>Pharmacokinetic parameters for plasma formoterol Cmax</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Formoterol PK Parameters (Cmax)</title>
          <description>Pharmacokinetic parameters for plasma formoterol Cmax</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="3.8" lower_limit="-120" upper_limit="150"/>
                    <measurement group_id="O2" value="13.2" spread="4.5" lower_limit="-63" upper_limit="135"/>
                    <measurement group_id="O3" value="11.9" spread="4.0" lower_limit="-99" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Formoterol PK Parameters (ke)</title>
        <description>Pharmacokinetic parameters for plasma formoterol ke</description>
        <time_frame>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</time_frame>
        <population>Subjects with an evaluable profile for this analyte</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Formoterol PK Parameters (ke)</title>
          <description>Pharmacokinetic parameters for plasma formoterol ke</description>
          <population>Subjects with an evaluable profile for this analyte</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.142" spread="0.035" lower_limit="-120" upper_limit="150"/>
                    <measurement group_id="O2" value="0.135" spread="0.025" lower_limit="-63" upper_limit="135"/>
                    <measurement group_id="O3" value="0.126" spread="0.032" lower_limit="-99" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Potassium Change From Baseline</title>
        <time_frame>12 hours</time_frame>
        <population>All subjects in the Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + PT001</title>
            <description>Placebo + Glycopyrrolate MDI 72 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PT005</title>
            <description>Placebo + Formoterol Fumarate 9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT001 + PT005</title>
            <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + PT003</title>
            <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Potassium Change From Baseline</title>
          <population>All subjects in the Safety Population</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="4.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.5" upper_limit="4.9"/>
                    <measurement group_id="O3" value="4.1" lower_limit="3.7" upper_limit="4.8"/>
                    <measurement group_id="O4" value="4.2" lower_limit="3.8" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events and serious adverse events were collected from the time the subject signed consent until final visit or discontinuation visit.</time_frame>
      <desc>Safety population included all participants who received investigational drug; participants were included in safety population according to the investigational drug they were receiving at the time of the event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo + PT001</title>
          <description>Placebo + Glycopyrrolate MDI 72 µg</description>
        </group>
        <group group_id="E2">
          <title>Placebo + PT005</title>
          <description>Placebo + Formoterol Fumarate 9.6 µg</description>
        </group>
        <group group_id="E3">
          <title>PT001 + PT005</title>
          <description>Glycopyrrolate 72 mcg + Formoterol Fumarate 9.6 µg (taken in any order)</description>
        </group>
        <group group_id="E4">
          <title>Placebo + PT003</title>
          <description>Placebo + Glycopyrrolate 72 µg/ Formoterol Fumarate µg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics Inc.</organization>
      <phone>605-305-2600</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

